Corcept Therapeutics

News

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

FDA declines to approve Corcept's rare disorder drug

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

Oncology

Interview at ESMO 2025 with Adrian Jubb and Roberto Vieira from Corcept Therapeutics

ESMO25: On helping patients with high unmet need, with Rober...

Oncology

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

Corcept gets FDA OK for first-in-class ovarian cancer drug

Ovarian cancer data restores faith in Corcept's relacorilant

11 high-impact drugs to look out for in 2026

FDA declines to approve Corcept's rare disorder drug

ESMO25: On helping patients with high unmet need, with Rober...

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

AI predicts liver cancer risk with "high accuracy"

Using AI-driven synthetic personas to take your insights fur...

Corcept Therapeutics

Editor's Picks